I am a Gastroenterologist and Hepatologist with an interest immune-mediated liver diseases. As a Wellcome trust clincial PhD fellow, my current research focuses on using genetic risk associations for primary sclerosing cholangitis (PSC) to understand the genes, cell types and biological mechanisms causing this debilitating disease.
I qualified as a medical doctor in 2009 from Imperial College, London with an intercalated BSc in Medical Sciences with Haematology. My undergraduate research focused on deciphering the function of N-linked glycosylation sites on the synthesis and function of von Willebrand Factor, a blood glycoprotein with an essential role in haemostasis. In 2011, I commenced an Academic Clinical Fellowship in Gastroenterology, and quickly developed and interest in immune-mediated liver diseases, specifically primary sclerosing cholangitis (PSC). Alongside my clinical training in Gastroenterology and Hepatology, I spent several years working with the UK-PSC Consortium (http://www.uk-psc.com/) to develop a risk scoring system for adverse patient outcomes, using clinical phenotype data from 1000 patient recruited to the UK-PSC Genetics Study. The collaboration between UK-PSC and the Anderson group led to my joining the Anderson team in 2016 as a Wellcome Trust Clinical PhD Fellow. Here, my work focuses on furthering our understanding of genetic risk variants through RNA sequencing of PSC-relevant tissues. My extra-medical interests include running around after my young daughter, playing the violin and contesting parking penalty notices.
Comparison of risk scores in the PSC arena.
Hepatology (Baltimore, Md.) 2019
Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.
Hepatology (Baltimore, Md.) 2019;69;5;2120-2135
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.
Nature genetics 2017;49;2;269-273
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.
A review of the medical treatment of primary sclerosing cholangitis in the 21st century.
Therapeutic advances in chronic disease 2016;7;1;68-85
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function.
A rare cause of cholangiopathy.
Mesenteric fat as a source of CRP and target for bacterial translocation in Crohn's disease.
Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor.